Private Advisor Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Private Advisor Group’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,794	Closed	-$142	–	2021
2022 Q4	$142	Buy	+11,794	New	+$91.7K	﹤0.01%	1548
2022 Q2	–	Sell	-12,752	Closed	-$110K	–	2210
2022 Q1	$110K	Hold	12,752	–	–	﹤0.01%	1983
2021 Q4	$182K	Buy	12,752 +575	+5%	+$12K	﹤0.01%	1948
2021 Q3	$268K	Buy	12,177 +666	+6%	+$11.3K	﹤0.01%	1755
2021 Q2	$154K	Buy	+11,511	New	+$132K	﹤0.01%	1862

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SIGI

Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Private Advisor Group's ORMP Position: Q1 2023 in Review

Private Advisor Group sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 11,794 shares — an estimated $142 sold.

Private Advisor Group first reported a position in ORMP in Q2 2021 and held it in 5 quarters. The position peaked at $268K in Q3 2021. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

Private Advisor Group reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Private Advisor Group sold 11,794 Oramed Pharmaceuticals shares in Q1 2023, an estimated $142.
Private Advisor Group first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 5 quarters.
Private Advisor Group's Oramed Pharmaceuticals position peaked at $268K in Q3 2021.
61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Private Advisor Group's 13F filing for Q1 2023, filed 10 May 2023.